Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 12;6(1):18.
doi: 10.1038/s41572-020-0149-1.

Hidradenitis suppurativa

Affiliations
Review

Hidradenitis suppurativa

Robert Sabat et al. Nat Rev Dis Primers. .

Abstract

Hidradenitis suppurativa (HS; also designated as acne inversa) is a chronic inflammatory disorder, which affects the intertriginous skin and is associated with numerous systemic comorbidities. The estimated prevalence of HS is ~1% in most studied countries. Typically starting in early adulthood, cutaneous inflamed nodules, abscesses and pus-discharging tunnels develop in axillary, inguinal, gluteal and perianal body sites. The comorbidities of HS include metabolic and cardiovascular disorders, which contribute to reduced life expectancy. A genetic predisposition, smoking, obesity and hormonal factors are established aetiological factors for HS. Cutaneous changes seem to start around hair follicles and involve activation of cells of the innate and adaptive immune systems, with pivotal roles for pro-inflammatory cytokines such as tumour necrosis factor, IL-1β and IL-17. The unrestricted and chronic immune response eventually leads to severe pain, pus discharge, irreversible tissue destruction and scar development. HS has profound negative effects on patients' quality of life, which often culminate in social withdrawal, unemployment, depression and suicidal thoughts. The therapeutic options for HS comprise antibiotic treatment, neutralization of tumour necrosis factor and surgical intervention together with lifestyle modification. Nevertheless, there is an enormous need for awareness of HS, understanding of its pathogenesis and novel treatments.

PubMed Disclaimer

Comment in

References

    1. Saunte, D. M. L. & Jemec, G. B. E. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 318, 2019–2032 (2017). - PubMed - DOI - PMC
    1. Ingram, J. R. et al. Population-based clinical practice research datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa. Br. J. Dermatol. 178, 917–924 (2018). This paper is a well-conducted registry study providing a realistic estimate of HS prevalence. - PubMed - DOI - PMC
    1. Theut Riis, P., Thorlacius, L., Knudsen List, E. & Jemec, G. B. E. A pilot study of unemployment in patients with hidradenitis suppurativa in Denmark. Br. J. Dermatol. 176, 1083–1085 (2017). - PubMed - DOI - PMC
    1. Matusiak, L., Bieniek, A. & Szepietowski, J. C. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J. Am. Acad. Dermatol. 62, 706–708 (2010). - PubMed - DOI - PMC
    1. Wolk, K. et al. Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa. J. Immunol. 186, 1228–1239 (2011). This paper is the first investigation of the role of cytokines related to activated lymphocytes (for example, IL-17, IL-22, IL-26 and IFNγ) and myeloid cells (for example, IL-1β and IL-10), the elements of their pathways and their consequences in the skin of patients with HS. - PubMed - DOI - PMC

Publication types

MeSH terms

Substances